NXTC Research and Charts

NXTC - NextCure Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-05 (Delayed quote data 2025-05-09)

Last 0.45	Change ⇑ +0.06 (+0.00%)	Volume 512,370
	Open 0.39	High 0.45	Low 0.39

8EMA (Daily) 0.43	40EMA (Daily) 0.48	50EMA (Daily) 0.51	STO (Daily) 49.492	MACD Hist (Daily) 0.013
8EMA (Weekly) 0.475	40EMA (Weekly) 0.89	50EMA (Weekly) 0.98	STO (Weekly) 28.169	MACD Hist (Weekly) -0.003


Company Profile
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. It is focused on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. The company's product candidate, NC318, is an immunomedicine against an immunomodulatory receptor called Siglec-15, or S15.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.